September 30th, Gelonghui | Prime Medicine (PRME.US) surged by about 45%, reaching a peak of $5.02. On the news front, Prime Medicine signed a research collaboration and licensing agreement with Bristol-Myers Squibb, agreeing to jointly develop and commercialize multiple therapies. According to the agreement, Bristol-Myers Squibb will invest $55 million to purchase Prime's equity, and Prime will receive a $55 million upfront payment. Once certain sales and development milestones are reached, the upfront payment could exceed $3.5 billion.
美股异动丨Prime Medicine大涨约45% 与施贵宝签署研究合作与许可协议
U.S. stock market anomaly | Prime Medicine soared about 45%, signed a research collaboration and license agreement with bristol-myers squibb.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.